Analysis for BIIB

📈 Growth & Financial Trajectory

Over 8 quarters, Revenues rose from $2.465B (2024Q2) to $2.736B (2026Q2), about an 11% gain. However, Net Income declined from $583.6M to $97.5M, with a peak of $466.5M in 2025Q3 and a small loss in late 2025, signaling earnings volatility despite growing top line. The trend shows a mid-2025 rebound in profitability even as the 2026 quarter demonstrates upside in revenue.

💰 Margins & Cash Flow

Gross Margin stayed high around 70%–77% across quarters; Operating Margin improved from roughly 30% (2024) to mid-40s% by 2026Q2. Net cash flow from operating activities was consistently positive, peaking at about $1.27B in 2025Q3 and about $0.45B in 2026Q2, while investing cash flow remained a cash outflow and financing varied.

🛡️ Balance Sheet & Liquidity

Current Assets ranged about $7.1B–9.0B vs Current Liabilities $3.0B–4.0B; Long-term Debt around $6.28B; Equity near $18.0B–19.0B. Liquidity cushion appears solid, supported by consistent operating cash flow.

⚠️ Key Drivers & Risks

• Drivers: Pipeline momentum in immunology/neurology; durable portfolio demand.
• Risks: Earnings volatility; regulatory/pipeline execution risk; sensitivity to biotech cycles.